Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Kemurnian >98,0% (HPLC) Lenvatinib Mesylate Intermediate Factory
Pasokan Kimia Ruifu Lenvatinib Mesylate Intermediates Kanthi Kemurnian Dhuwur
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimetil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jeneng Kimia | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
sinonim | Lenvatinib Impurity 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Nomer CAS | 205448-66-4 |
Nomer CAT | RF-PI1970 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C12H10ClNO3 |
Bobot Molekul | 251.67 |
Titik didih | 377,4 ± 37,0 ℃ |
Kapadhetan | 1,320±0,06 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Padhet Putih nganti Kuning |
1 H NMR Spektrum | Konsisten karo Struktur |
Kemurnian / Metode Analisis | > 98,0% (HPLC) |
Mundhut ing Pangatusan | <1.00% |
Total Impurities | <2.00% |
Test Standar | Standar Perusahaan |
Panggunaan | Intermediate/Impurity saka Lenvatinib Mesylate (CAS: 857890-39-2) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) minangka perantara saka Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib minangka obat kanker tiroid sing dikembangake dening Eisai Corporation of Japan (Kode: E7080), kagolong ing inhibitor multi-reseptor tyrosine kinase (RTK) lisan lan bisa nyandhet aktivitas kinase saka faktor pertumbuhan endothelial vaskular Reseptor R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Lenvatinib uga bisa nyandhet keterlibatan RTK liyane ing angiogenesis patologis, pertumbuhan tumor, lan perkembangan kanker kajaba fungsi seluler normal kalebu reseptor faktor pertumbuhan fibroblast (FGF) FGFR1, 2, 3, lan 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, lan RET.[Indikasi]: Lenvatinib cocok kanggo perawatan pasien kanker tiroid saka jinis kambuh utawa metastasis lokal, jinis progresif lan jinis diferensiasi yodium-refraktori radioaktif.